Page 88 - Express Scripts News Today

A key House panel has joined the chorus of critics railing against pharmacy benefit managers, increasing government pressure on several major health care companies. Oversight and Accountability Committee Chair James Comer (R-Ky.) is the latest official to launch an investigation into the what he…

As well as putting pressure on other makers, it could focus attention on pharmacy benefit middlemen.

Healthcare

Pharmacy benefit managers such as CVS Caremark, Cigna's Express Scripts and UnitedHealth Group's OptumRx are under increasing government scrutiny.

Systemic issues with TriCare include rising costs, a declining number of participating health care providers, and a loss of community pharmacy access

James Comer (R-Ky), House Committee on Oversight and Accountability chairman, sent letters to the Office of Personnel Management, Centers for Medicare and Medicaid Services and the Defense Health Agency asking for documents that show how PBMs’ practices are affecting federal government healthcare programs. In addition, he sent letters to CVS Caremark, Express Scripts and OptumRx, asking them to provide information on their tactics.

Company Representatives: Doug Hirsch - Co-Founders, Co-Chief Executive Officer Trevor Bezdek - Co-Founders, Co-Chief Executive Officer Karsten Voermann - Chief Financial Officer Aubrey Reynolds - Senior...

Florida lawmakers are about to make big decisions about your healthcare when the 2023 Legislative Session convenes on Tuesday. Topics include everything from abortion to physician-assisted suicide to what's considered telehealth.

Dear Colleague, It's getting hot. And all of us at NCPA couldn't be happier about it. I'm not talking about thermometers here. NCPA has kept after PBMs for years, with lots of heat and pressure. But now, we have company. The Federal Trade Commission, the Senate, consumers, physicians, and state legislatures are in our corner, and we're grateful for the company.

Operator: Ladies and gentlemen, thank you for standing by. And welcome to Arcutis Biotherapeutics, Inc. Fourth Quarter 2022 Earnings Conference Call.